This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MedTech Stock Q4 Earnings Slated for Jan 30: SYK, ZBH, ALGN
by Zacks Equity Research
The Medical sector is expected to stand out on favorable consumer behavior, growing prevalence of minimally-invasive surgeries, demand for liquid biopsy tests, and a value-based payment system.
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Top Research Reports for Microsoft, Philip Morris and 3M
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Philip Morris (PM) and 3M (MMM).
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.
Stryker (SYK) Posts Upbeat Preliminary Sales Figure for Q4
by Zacks Equity Research
Stryker Corporation's (SYK) fourth quarter and 2017 preliminary net sales figures are encouraging, courtesy of balanced revenue growth in all business segments.
Stryker's Global Foothold Strong Amid Product Recall Issue
by Zacks Equity Research
Stryker (SYK) enjoys strong foothold in the European and Australian markets. On the flip side, the company witnesses lower demand for health care products.
Company News For Dec 8, 2017
by Zacks Equity Research
Companies In The News are: CONN,GEF,LULU,SYK,ENTL
Stryker (SYK) Up 4.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Stryker (SYK) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker (SYK) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Stryker Corporation (SYK) saw its shares rise over 7% on the day after the company reported better-than-expected third-quarter results.
Top Stock Reports for Amgen, Comcast & McDonald's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Comcast (CMCSA), and McDonald's (MCD).
MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More
by Zacks Equity Research
Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.
MedTech Growing on Emerging Markets, M&A: Stocks to Buy
by Zacks Equity Research
Given the current lack of clarity, let???s concentrate on some powerful long-term tailwinds of the medical device industry like emerging market expansion, mergers & acquisitions (M&A), positive demographic trends and new product innovation.
Will Sage-Unit Recall Hurt Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
In August, Stryker (SYK) announced a voluntary recall of the Oral Care line-up, which was offered by the company's Sage-Products unit.
NuVasive's TLX Interbody System Gets Expanded FDA Approval
by Zacks Equity Research
NuVasive (NUVA) leaves no stone unturned to cash in on the rapidly-evolving spine market.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse portfolio and accretive acquisitions is instrumental in aiding the company's top-line growth.
3 Plastic & Reconstructive Surgery Stocks Looking Good
by Zacks Equity Research
Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker Corporation (SYK) has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.
NuVasive Acquires Vetera Spine, Grows With Spinal Hardware
by Zacks Equity Research
NuVasive aims to market and distribute Vetera Spine's FDA-approved COHERE Cervical and COALESCETM Lumbar Interbody fusion devices in the United States.
Mazor Robotics' CE Mark for Mazor X Platform to Drive Orders
by Zacks Equity Research
Mazor Robotics and Medtronic will now be able to market and sell the Mazor X Surgical Assurance Platform in countries that recognize the CE Mark.
Model N (MODN) Rides on Revitas Buyout and Customer Wins
by Zacks Equity Research
Model N (MODN) is gaining from positive synergies from the Revitas acquisition and frequent client wins.
The Zacks Analyst Blog Highlights: Mondelez, Colgate-Palmolive, Stryker, Nike and Fifth Third Bancorp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mondelez, Colgate-Palmolive, Stryker, Nike and Fifth Third Bancorp
Top Research Reports for Mondelez, Colgate-Palmolive & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mondelez (MDLZ), Colgate-Palmolive (CL) and Stryker (SYK).
NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite
by Zacks Equity Research
NuVasive (NUVA) to add three-dimensional porous interbody technology across polyetheretherketone (PEEK) material as well through the Vertera Spine buyout.
Accuray (ARAY) Grapples With Falling Margin and Product Mix
by Zacks Equity Research
Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.
NuVasive (NUVA) to Expand San Diego Global Headquarters
by Zacks Equity Research
Apart from introducing sophisticated features at the facility, NuVasive (NUVA) plans to open an innovation center of excellence at the San Diego global headquarters.